16Aug 2024
Improving CKD Outcomes: SGLT2 Inhibitors and Early Screening

Improving CKD Outcomes: SGLT2 Inhibitors and Early Screening

Chronic kidney disease (CKD) affects 13% of the global population, with higher rates among those with type 2 diabetes (T2D). Early diagnosis and intervention are crucial, yet barriers persist due to under-recognition and limited screening. Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer proven renoprotective benefits. This review explores the evidence, highlights diagnostic challenges, and advocates for improved screening programs and the integration of high-tech tools in CKD management.

  • #endo-diabetology

Like

Save

Share